Bristol Myers Squibb
Camzyos
obstructive hypertrophic cardiomyopathy
Resolved
176days ago
Phase 3 readout · Jan 12, 2026
What's at stake
Phase 3 trial results for Camzyos in obstructive hypertrophic cardiomyopathy are due Jan 12, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Camzyos ® (mavacamten) January 12 Announced positive topline results from the Phase 3 SCOUT-HCM trial evaluating Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.”